Physician profile
Michael L Doyal
NPI 1750544672
$2,929.15
in general payments reported to CMS, 2019-2025
18 companies · $986 in 2025
The $986 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $380 · 2023: $618 · 2024: $687 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $442.33 | 2022-2024 | Breztri, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $342.36 | 2021-2025 | |
| Novo Nordisk INC | $331.51 | 2021-2025 | Wegovy, Ozempic |
| Abbvie INC. | $261.60 | 2022-2023 | |
| Astellas Pharma US INC | $250.00 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $225.00 | 2022-2023 | Arexvy |
| Insulet Corporation | $169.25 | 2025 | Omnipod |
| Medtronic, INC. | $155.79 | 2024 | Signia |
| Ars Pharmaceuticals Operations, INC. | $126.27 | 2025 | Neffy |
| Biohaven Pharmaceuticals, INC. | $112.52 | 2021 | |
| Kyowa Kirin, INC. | $110.41 | 2025 | |
| Genzyme Corporation | $106.11 | 2022 | |
| Neurocrine Biosciences, INC. | $96.00 | 2023 | Ingrezza |
| Amgen INC. | $51.91 | 2023 | Repatha |
| Phathom Pharmaceuticals, INC. | $51.26 | 2025 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.56 | 2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.29 | 2023 | Xifaxan |
| Akebia Therapeutics INC | $16.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Doyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.